July 8 (Reuters) - Britain's Smiths Group on
Wednesday said it would help produce a blood-based COVID-19
antibody test approved by the country's regulators, another move
by the technology firm to develop products to combat the
pandemic.
The London-listed company said it has agreed with
biopharmaceutical firm Attomarker, for an undisclosed amount, to
make its portable, triple antibody test device at unit Smiths
Detection's site in Hemel Hempstead, England.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard
Orr)